← Browse by Condition
Medical Condition
msi high
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, EARLY_Phase 1
NCT06362369 Phase 1, Phase 2
Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Enrollment
126 pts
Location
United States
Sponsor
7 Hills Pharma, LLC
NCT06305962 EARLY_Phase 1
Recruiting
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Enrollment
30 pts
Location
Australia
Sponsor
Radiopharm Theranostics, Ltd